Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
52 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
OncoMed Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'OncoMed Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the OncoMed Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of OncoMed Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of OncoMed Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of OncoMed Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the OncoMed Pharmaceuticals, Inc.'s pipeline products Reasons to buy - Evaluate OncoMed Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of OncoMed Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the OncoMed Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of OncoMed Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of OncoMed Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of OncoMed Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 OncoMed Pharmaceuticals, Inc. Snapshot 5 OncoMed Pharmaceuticals, Inc. Overview 5 Key Information 5 Key Facts 5 OncoMed Pharmaceuticals, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 OncoMed Pharmaceuticals, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 OncoMed Pharmaceuticals, Inc. - Pipeline Products Glance 13 OncoMed Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 OncoMed Pharmaceuticals, Inc. - Early Stage Pipeline Products 15 IND/CTA Filed Products/Combination Treatment Modalities 15 Preclinical Products/Combination Treatment Modalities 16 OncoMed Pharmaceuticals, Inc. - Drug Profiles 17 demcizumab 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 tarextumab 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 ipafricept 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 OMP-52M51 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 vantictumab 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 OMP-305B83 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Biologic for Cancer 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Biologic to Inhibit Wnt Pathway for Cancer 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Monoclonal Antibody to Inhibit Other Pathways for Cancer 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 OMP-131R10 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Small Molecules for Oncology 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 OncoMed Pharmaceuticals, Inc. - Pipeline Analysis 34 OncoMed Pharmaceuticals, Inc. - Pipeline Products by Target 34 OncoMed Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 35 OncoMed Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 36 OncoMed Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 37 OncoMed Pharmaceuticals, Inc. - Recent Pipeline Updates 38 OncoMed Pharmaceuticals, Inc. - Dormant Projects 49 OncoMed Pharmaceuticals, Inc. - Locations And Subsidiaries 50 Head Office 50 Appendix 51 Methodology 51 Coverage 51 Secondary Research 51 Primary Research 51 Expert Panel Validation 51 Contact Us 52 Disclaimer 52
List of Tables OncoMed Pharmaceuticals, Inc., Key Information 5 OncoMed Pharmaceuticals, Inc., Key Facts 5 OncoMed Pharmaceuticals, Inc. - Pipeline by Indication, 2014 8 OncoMed Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 9 OncoMed Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 10 OncoMed Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014 11 OncoMed Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 12 OncoMed Pharmaceuticals, Inc. - Phase II, 2014 13 OncoMed Pharmaceuticals, Inc. - Phase I, 2014 14 OncoMed Pharmaceuticals, Inc. - IND/CTA Filed, 2014 15 OncoMed Pharmaceuticals, Inc. - Preclinical, 2014 16 OncoMed Pharmaceuticals, Inc. - Pipeline by Target, 2014 34 OncoMed Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 35 OncoMed Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 36 OncoMed Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 37 OncoMed Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 38 OncoMed Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 49
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.